Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Search

Top

THE INSTITUTE FOR CANCER RESEARCH Philadelphia PA 19111 USA

UEI: SLED_C056F92EEB64163A

THE INSTITUTE FOR CANCER RESEARCH Philadelphia PA 19111 USA is a federal contractor, registered under UEI SLED_C056F92EEB64163A. It has been awarded $149,995,010 in federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_C056F92EEB64163A

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

The Institute for Cancer Research specializes in preclinical drug and vaccine development. Their core capabilities include providing a structured approach to moving therapeutic candidates from the discovery phase into clinical application, with specific expertise in efficacy testing and preclinical ...

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

1

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency

Department Of Health And Human Services$150.0M100%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$150.0M100%

Awards by Agency Over Time

Awards by Place of Performance

Compete with THE INSTITUTE FOR CANCER RESEARCH Philadelphia PA 19111 USA

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for THE INSTITUTE FOR CANCER RESEARCH Philadelphia PA 19111 USA

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in THE INSTITUTE FOR CANCER RESEARCH Philadelphia PA 19111 USA's top NAICS codes and agencies

High-Containment Laboratory & Scientific Research ServicesThis subcontract opportunity, titled High-Containment Laboratory and Scientific Research Services, supports the National Institutes of Health Olao under the Department of Health and Human Services. The project focuses on the NIH STEAM program, requiring the provision of specialized scientific personnel to perform basic, translational, and clinical research, as well as laboratory services and scientific computing. Work is primarily based in Bethesda and involves critical operations within BSL-1 through BSL-4 and ABSL-1 through ABSL-4 containment environments. Qualified providers must demonstrate a proven capability to operate within these high-containment facilities and deliver expert research execution and animal-care roles. This opportunity is designated as a partial Small Business Set Aside under NAICS code 541714. The solicitation was posted on November 10, 2026, with a response deadline of November 17, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract

Solicitation # HT942627RE002

The Defense Health Agency Contracting Activity intends to issue a Request for Proposal in early November 2026 for an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle. This opportunity is specifically set aside for small businesses certified under the Small Business Administration 8(a) Program and will focus on providing military medical research and development services. Multiple new awards are expected, all of which will align with the existing unrestricted contract vehicle. The OMNIBUS IV vehicle operates with a cumulative ceiling of 10 billion dollars and a performance period extending through June 19, 2032, including option years. To date, the contract has seen over 690 million dollars awarded across 61 task orders to various end users, including the Naval Supply Systems Command and the Uniformed Services University of the Health Sciences. Task orders may be competed via fair opportunity or through specific exceptions such as small business set-asides.

Defense Health Agency

POSTED

DEADLINE

DNA Sequencing Service

Solicitation # PCA-NIEHS-00080

The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, is conducting a market survey via a Sources Sought notice for an indefinite-delivery indefinite-quantity (IDIQ) contract to provide DNA sequencing services and associated bioinformatics support. The anticipated five-year period of performance involves processing an estimated 2,000 to 3,000 samples per month, including yeast colonies, plasmid DNA, and PCR-generated samples from human and rodent species. While high-throughput whole-plasmid sequencing is required for a small volume, Sanger sequencing will be the primary method. The contractor must ensure a Phred-equivalent quality score greater than 20 within the reportable region, with an average target region size of 700 to 1,000 base pairs. The selected provider will be responsible for providing all sample collection materials, prepaid shipping containers, and maintaining sample retention for at least 180 days. Deliverables must be provided in specific formats, including .ab1, .seq, .scf, .phd.1, .txt, and .fasta/.fa, with turnaround times of two business days for plasmid DNA or PCR amplicon samples and five business days for genomic DNA requiring PCR amplification. The government is specifically seeking capability statements from small businesses, including 8(a), SDB, WOSB, HUBZone, and VOSB concerns, to determine the appropriate acquisition method. Responses must be submitted by November 12, 2026, and include a capability statement not exceeding seven pages, along with the entity's UEI, TIN, and business size certification.

National Institutes Of Health Olao

POSTED

DEADLINE

in about 23 hours

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

BWA Identification Core & Assay DevelopmentThe BWA Identification Core and Assay Development subcontract, managed under the Department of Defense agency W6QK Acc-Apg, focuses on the creation and supply of core biological detection technology and assays for U.S. Navy EMBD IDS projects. The primary objective is to develop assays capable of identifying toxins, viruses, and bacteria with sensitivity and specificity levels that match laboratory PCR standards. To ensure accuracy, the project utilizes biological agent panels and simulants during the testing phase. The scope of work requires the delivery of a biological detection engine, specialized assay kits, and comprehensive performance data. This effort is categorized under NAICS code 541714 and is slated for performance in Gunpowder. The solicitation was posted on November 6, 2026, with a response deadline set for December 7, 2026.

POSTED

DEADLINE

Solicitation # DARPA-PS-26-137

The Firefox program, managed by the DARPA Biological Technologies Office, is a 36-month, three-phase initiative seeking to develop a 100-channel, non-invasive brain-computer interface with 50-micron spatial and 100-microsecond temporal resolution. The program focuses on two primary technical hurdles: the creation of components for dynamic rastering and scanning of coherent optical signals to target multiple regions of interest, and the development of non-digital data processing architectures capable of handling high data rates and computational burdens. Multiple awards are anticipated, with funding ranging between 4 million and 7 million dollars per award. Awards will be issued as Other Transaction for Prototype agreements under 10 U.S.C. 4022, utilizing a milestone-based payment schedule. The selection process is multi-staged, beginning with an abstract evaluation based on technical comprehension, technical ability, and budget realism, followed by an Oral Presentation Proposal for selected candidates. Proposers must be registered in the System for Award Management and possess a Unique Entity Identifier. Key compliance requirements include adherence to ANSI laser safety limits for human tissue exposure, Cybersecurity Maturity Model Certification, and strict guidelines regarding organizational conflicts of interest and foreign influence risk assessments.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Future Program: Laguna

Solicitation # DARPA-SN-27-15

Special Notice DARPA-SN-27-15, issued by the Defense Advanced Research Projects Agency Biological Technologies Office, serves as a public notification for the forthcoming Laguna program. This notice is intended for information and program planning purposes and does not constitute a formal solicitation for proposals. The program is anticipated to be a 36-month effort focused on the development and demonstration of defense-relevant specialty products formulated from U.S.-produced raw materials. These products must meet or exceed the critical performance requirements of existing military materials. Key deliverables for the program include predictive tools for material properties, life cycle assessments, technoeconomic analyses, and commercialization strategy plans. The primary point of contact for the initiative is Dr. William Mounfield. While this notice provides an overview of research interests, DARPA will not accept submissions at this time. Formal solicitation details and submission instructions will be posted on sam.gov upon release. All communications regarding this notice must remain unclassified.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)The National Institutes of Health is seeking research projects to investigate the initiation and early progression of Type 1 Diabetes using human-relevant New Approach Methodologies. Utilizing human cells, tissues, organoids, and microphysiological systems, the initiative aims to identify early biomarkers and therapeutic targets to prevent significant pancreatic beta cell loss. This effort focuses on combining innovative experimental and computational approaches to uncover the cellular and molecular mechanisms driving the disease. Selected awardees will join the Human Islet Research Network to foster collaboration, share data and tools, and coordinate the use of limited human pancreatic tissues. With total program funding of 12 million dollars and an expected 12 awards, the project is scheduled to begin around November 1, 2027. The overarching goal is to accelerate the translation of research discoveries into practical preventive and treatment strategies through a harmonized, multi-laboratory effort.

National Institutes Of Health

POSTED

DEADLINE

Cooperative Agreement for affiliated Partner with Rocky Mountain Cooperative Ecosystem Studies Unit

Solicitation # G27AS00062

The U.S. Geological Survey is seeking a partner within the Rocky Mountain Cooperative Ecosystem Studies Unit to establish a cooperative agreement for research aimed at improving Chronic Wasting Disease surveillance. The project focuses on developing a robust, automated, and reproducible analytical pipeline to standardize Real-Time Quaking Induced Conversion assay data analysis, reducing the reliance on subjective interpretation. Key deliverables include the creation of machine-learning models using LSTM, CNN-LSTM, or hybrid architectures to classify fluorescence curves, the development of an open-source application via R-Shiny or Streamlit/Python for data ingestion and visualization, cross-laboratory validation across at least three independent facilities, and a peer-reviewed publication. The total program funding is estimated at 145,220 dollars for a single award, with an anticipated period of performance from April 1, 2027, to March 31, 2032. Applications must be submitted through grants.gov by December 8, 2026, and are evaluated based on purpose and relevance, technical approach, qualifications and past performance, and budget clarity. Recipients must comply with Department of the Interior general terms, geospatial data standards under the Geospatial Data Act of 2018, and federal regulations regarding financial reporting and conflict of interest. Required submission documents include a Project Abstract Summary, Biographical Sketches, and Current and Pending Support forms for all senior key personnel.

US Geological Survey

POSTED

DEADLINE

Cooperative Agreement for affiliated Partner with Gulf Coast Cooperative Ecosystem Studies Unit

Solicitation # G27AS00064

The U.S. Geological Survey Eastern Ecological Science Center is soliciting applications for a Cooperative Agreement under the Gulf Coast Cooperative Ecosystem Studies Unit to perform bioinformatic analysis on avian microbiome metatranscriptomic datasets. The research focuses on genome assembly-based identification of viruses, prokaryotic, and eukaryotic microorganisms, with a specific emphasis on zoonotic and wildlife pathogens. Awardees will analyze shotgun metatranscriptomic data to estimate microbial diversity and abundance across various host species, tissues, and geographic regions, while developing reproducible bioinformatic workflows. Key requirements include collaborating on peer-reviewed publications and making data products publicly available through repositories like ScienceBase or the National Center for Biotechnology Information. The solicitation, numbered G27AS00064, has a total program funding ceiling of 459,000 dollars for one expected award. The anticipated period of performance runs from April 1, 2027, to March 31, 2030, with applications due via grants.gov by December 7, 2026. Proposals are evaluated based on purpose and relevance, technical approach, qualifications and past performance, and budget clarity. Applicants must be registered in SAM.gov and provide specific documentation, including a Project Abstract Summary, Biographical Sketches, and Current and Pending Support forms for key personnel. All geospatial data produced must adhere to Federal Geospatial Data Committee standards and the Geospatial Data Act of 2018.

US Geological Survey

POSTED

DEADLINE

in about 2 months

Specialized Bio-Research / Protocol Compliance ConsultantThis subcontract opportunity is for a Specialized Bio-Research / Protocol Compliance Consultant to support research and development projects for the United States Navy and Marine Corps Systems Command. The selected provider will conduct research involving recombinant DNA and human or animal subjects, ensuring all activities are executed according to strict research protocols. Key responsibilities include managing recombinant DNA activities within laboratory facilities and maintaining full compliance with federal, state, and local environmental laws regarding the handling of toxic materials. All work must be performed under the necessary IRB and IACUC approvals, with the final deliverables consisting of experimental data and feasibility reports. The contract is designated as a Total Small Business Set-Aside under NAICS code 541714, specifically targeting firms with fewer than 500 employees in alignment with SBIR/STTR mandates. Interested parties must submit their responses by December 2, 2026. This role is critical for prime contractors requiring specialized expertise in bio-research compliance and the technical execution of complex laboratory protocols within the Department of Defense framework.

United States Navy

POSTED

DEADLINE

Biolab Mirror: Artificial Intelligence / Machine Learning (AI/ML) Digital Twin for Intent Characterization and Bio-Containment Integrity

Solicitation # DTR27TZ02-NV001

The Defense Threat Reduction Agency, under the Department of War, is soliciting proposals for the Biolab Mirror, an AI/ML-driven Digital Twin designed to ensure bio-containment integrity and characterize intent in state-sponsored biological research facilities. The project implements a Physics-to-Mesh Zero Trust architecture that cross-validates digital telemetry from LIMS, SCADA, and BMS logs against unalterable physical and biological laws, such as thermodynamics and metabolic rates. This system aims to detect clandestine pathogen scaling and containment spoofing by identifying coherence failures. Beyond its defensive application, the Biolab Mirror will serve as a cyber-physical sandbox for simulating multi-domain attacks against high-containment infrastructure, filling a critical gap in current cyber-range emulation. This is a phased STTR program with a total small business set-aside. Phase I focuses on delivering a conceptual architecture and a working software prototype, while Phase II, with a ceiling price of 1.5 million dollars, involves full project effort over a 24-month duration. Proposals are evaluated based on technical merit, investigator qualifications, and commercial potential. Applicants must be registered in SAM and the SBA Company Registry. Compliance requirements include CMMC standards for safeguarding controlled unclassified information and strict adherence to organizational conflict of interest disclosures. Proposals must be submitted via the DSIP portal by January 6, 2026.

Defense Threat Reduction Agency

POSTED

DEADLINE

in about 2 months

Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-014

The National Institutes of Health (NIH) issued solicitation RFA-AI-28-014 to establish centers focused on the systems-level understanding of the links between infectious pathogens, inflammatory pathways, and chronic diseases. The program supports two types of centers: Chronic and Infectious Diseases Systems Biology Centers (CIDSB), which examine the bidirectional link between chronic and infectious diseases, and Systems Biology Inflammation Centers (SBI), which focus on the role of inflammation in chronic diseases to identify precision medicine targets. The primary goals are to develop predictive computational models for disease progression, discover novel drug targets and biomarkers, and create harmonized, FAIR-compliant cross-disease datasets. The total program funding is 26 million dollars, with an expected 10 awards and an individual award ceiling of 2.5 million dollars. Applications must be submitted electronically via Grants.gov by February 18, 2027. The proposal structure is multi-component, requiring an overall section, an administrative core, a data and modeling core, and a biospecimen collection and processing core, with additional requirements for research projects and optional cores depending on the center type. Evaluation is based on an overall impact score focusing on significance and the qualifications of the investigators. Awardees must comply with strict cybersecurity incident reporting requirements, notifying the HHS awarding agency within 48 hours of discovery, and must adhere to rigorous biosafety and human subjects protection standards. Applicants must maintain active SAM registration and UEI identifiers to be eligible for funding.

National Institutes Of Health

POSTED

DEADLINE

Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-014

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking proposals under solicitation RFA-AI-28-014 for the Systems Biology of Infection and Inflammation in Chronic Diseases. This initiative aims to advance the systems-level understanding of how infectious pathogens and inflammatory pathways contribute to the predisposition, onset, and progression of chronic diseases. The program emphasizes the integration of clinical and patient data, large-scale omics datasets, and advanced artificial intelligence and computational modeling to develop strategies for preventing, treating, and mitigating the combined effects of these conditions. This federal solicitation was posted on November 4, 2026, with a response deadline of February 19, 2027. It is important to note that clinical trials are not allowed under this specific funding opportunity. Interested parties can find further details through the provided grants portal.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

In Vivo Efficacy and Toxicology StudiesThis subcontract, titled In Vivo Efficacy and Toxicology Studies, supports the National Institutes of Health and the Department of Health and Human Services by providing preclinical validation of biologic therapies for prime contractors on NIH/NINDS ADRD projects. The scope of work involves executing in vivo efficacy, safety pharmacology, and toxicology studies utilizing translationally appropriate animal models specifically for Alzheimer's and Frontotemporal Dementia. To fulfill the requirements, the contractor must utilize GLP-compliant toxicology lab facilities to ensure regulatory standards are met. The primary deliverables include comprehensive preclinical validation reports and detailed toxicology data packages necessary for Investigational New Drug submission. The project is categorized under NAICS code 541714, with a response deadline set for October 10, 2028.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

Genome Editing Construct and Delivery System OptimizationThis subcontract focuses on the design and optimization of genome editing constructs and biologic delivery systems to support prime contractors on NIH/NINDS genomic therapy projects. The scope of work involves utilizing CRISPR/Cas technology along with viral and non-viral vectors to refine editing constructs and delivery mechanisms. The selected provider will be responsible for assessing critical metrics including bioactivity, target engagement, durability, pharmacokinetics, and bioavailability. The final deliverables for this engagement consist of optimized therapeutic leads accompanied by comprehensive bioactivity and pharmacokinetics data reports.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years

NCI Research Specialist (Clinician Scientist)The NCI Research Specialist subcontract involves providing leadership and implementation services for National Cancer Institute funded clinical trials on behalf of prime contractors. The selected clinician scientist will be responsible for writing and revising protocols for national cancer clinical trials, managing trials within a clinical trials office, and recruiting patients. Additionally, the role requires active participation in NCI scientific review, monitoring, and steering committees. Candidates must possess clinician scientist status and demonstrated experience in cancer clinical research. The contract requires a dedicated effort ranging from 2.4 to 4.8 person-months per year. This opportunity is associated with the National Institutes of Health under the Department of Health and Human Services, with a response deadline set for February 20, 2029.

National Institutes Of Health

POSTED

DEADLINE

in over 2 years

Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)

Solicitation # RFA-NS-28-012

The National Institutes of Health, under the Department of Health and Human Services, has issued solicitation RFA-NS-28-012 to support the translation of genome editing and biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). This includes Frontotemporal Dementia, Lewy Body Dementias, Vascular Contributions to Cognitive Impairment and Dementia, and Multiple Etiology Dementias. The program funds the entire translational pipeline, from therapeutic lead optimization and drug product development to IND-enabling studies and early first-in-human clinical evaluations. Key activities include optimizing editing constructs and delivery systems, demonstrating in vivo efficacy, conducting safety pharmacology and toxicology studies, and developing scalable manufacturing processes that align with regulatory expectations. The agency intends to commit 6 million dollars in both fiscal years 2028 and 2029, with an expected three awards and a maximum project period of five years. Individual annual budget caps are set at 1.3 million dollars in direct costs, increasing to 2.5 million dollars for projects involving clinical trials. Awards are governed by the Public Health Service Act and federal regulations 42 CFR Part 52 and 2 CFR Part 200. Evaluation is based on an Overall Impact Score considering significance, innovation, approach, investigator expertise, and environment, with a specific focus on the Target Product Profile and the use of quantitative Go/No-Go milestones. Eligible applicants include small businesses and other for-profit organizations. Requirements for submission include active registration in the System for Award Management, a Unique Entity Identifier, and eRA Commons accounts. Awardees must adhere to strict cybersecurity incident reporting protocols, notifying the agency within 48 hours of discovery, and must register applicable clinical trials with ClinicalTrials.gov. The solicitation features multiple application cycles with deadlines extending through October 10, 2028, and earliest start dates ranging from December 2027 to July 2029.

National Institutes Of Health

POSTED

DEADLINE

in almost 2 years